{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-02T00:45:53.885Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-02. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-02. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-02, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"CYTK\",\n  \"company\": \"Cytokinetics, Incorporated\",\n  \"investigation_summary\": \"Cytokinetics has a commercial product (MYQORZO/aficamten) newly launched in Q1 2026 following FDA approval Dec 2025 and EU launch June 2026. The stock is near all-time highs at $73.68 (52w high $80.20), up ~152% over 1 year, on strong MYQORZO early commercial traction. Insider Form 4 filings are extremely active in the last 14 days but ALL transactions reviewed were SELLs by directors and employees (exercise of options + immediate sale) — no open-market P/S purchases verified despite the cluster trigger. CEO Blum sold $446K on 04/29, EVP Malik exercised options and sold ~$270K on 05/05, Director Kaye sold $223K on 06/01, Director Parshall sold $370K on 06/01 — all at various price points. This is a high-quality company with real product traction but the stock is fully-valued (no forward PE given pre-profitability; EV/EBITDA N/A) and near its 52w ceiling. The insider cluster reflects compensation-related exercise-and-sell activity, not conviction buying.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 5,\n  \"structure_hints\": [\n    \"cc\",\n    \"strangle\"\n  ],\n  \"business_snapshot\": \"Cytokinetics is a South San Francisco biotech that successfully transitioned from R&D to commercial-stage with MYQORZO (aficamten), an allosteric cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). FDA approval came December 2025; U.S. commercial launch began January 2026; EU commercial launch in Germany began June 1, 2026. MYQORZO's pivotal SEQUOIA-HCM trial showed statistically significant pVO2 improvement vs placebo and MAPLE-HCM (vs metoprolol) demonstrated superiority on the primary endpoint with a +2.3 mL/kg/min LSM difference (p<0.0001). The company also has aficamten in Phase 3 ACACIA-HCM for non-obstructive HCM (data expected Q2 2026), omecamtiv mecarbil in HFrEF, and ulacamten in HFpEF. Sanofi commercializes MYQORZO in China; Bayer licenses it in Japan. The pipeline is funded by ~$1.07B cash/investments as of March 31, 2026 plus a $700M May 2026 equity raise.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 1340000,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-07-29\",\n      \"recent_eps_surprise_pattern\": \"Q1 2026 EPS -$1.67 actual vs -$1.65 est (slight miss); Q4 2025 beat on revenue; overall recent history shows small beats/misses near consensus.\",\n      \"guidance_raise_in_last_90d\": true,\n      \"named_catalysts\": [\n        {\n          \"type\": \"product\",\n          \"description\": \"ACACIA-HCM Phase 3 data readout for aficamten in non-obstructive HCM expected Q2 2026 — potential label expansion to nHCM, a much larger market opportunity\",\n          \"date_or_window\": \"Q2 2026 (expected)\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/cytokinetics-apos-rapid-growth-myqorzo-161747587.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"European MYQORZO launch in Germany commenced June 1, 2026; EU rollout to follow major markets through 2026\",\n          \"date_or_window\": \"Q2-Q4 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/cytokinetics-launches-myqorzo-aficamten-european-113000483.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"Supplemental NDA submitted to FDA in January 2026 for MAPLE-HCM data inclusion in MYQORZO label; potential approval Q4 2026 showing aficamten superiority vs metoprolol monotherapy\",\n          \"date_or_window\": \"Q4 2026 expected\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"earnings\",\n          \"description\": \"MYQORZO U.S. Q1 2026 net product revenue $4.8M — early launch metrics tracking ahead of internal expectations per management commentary\",\n          \"date_or_window\": \"Reported May 6, 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/cytk-q1-earnings-match-estimates-192400909.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": null,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": null,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": -3.8,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"Pre-profitability company with first commercial quarter just reported ($4.8M net product revenue Q1 2026). No forward P/E calculable yet; EV/EBITDA is N/M since EBITDA is negative. The stock has run +152% over one year and sits ~8% below its $80.20 all-time high, reflecting a fully-priced market response to the FDA approval in Dec 2025. Revenue trajectory: Q1 2026 total revenues $19.4M (vs $0 in prior year comparable). Full-year 2026 consensus revenue ~$109-110M suggests substantial ramp but remains speculative given early launch phase.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"B\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": true,\n      \"rsi_14\": 50.7,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": 5\n    },\n    \"price_context\": {\n      \"last_close\": 73.68,\n      \"ytd_return_pct\": 15.8,\n      \"from_52w_high_pct\": -8.1\n    },\n    \"filings_reviewed\": [\n      {\n        \"form\": \"10-K\",\n        \"filed\": \"2026-02-26\",\n        \"url\": \"https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm\",\n        \"key_takeaways\": [\n          \"FDA approved MYQORZO Dec 19, 2025 for oHCM; commercially available Q1 2026; EU approval Feb 2026; China NMPA approval Dec 2025\",\n          \"SEQUOIA-HCM: +1.8 mL/kg/min pVO2 improvement vs placebo (p=0.000002) at week 24 in Phase 3 oHCM trial\",\n          \"MAPLE-HCM: aficamten superiority over metoprolol on primary endpoint (+2.3 mL/kg/min LSM, p<0.0001) presented Aug 2025\",\n          \"Cash + investments ~$1.22B as of Dec 31, 2025; $700M equity raise May 2026 ($71/share), adding ~$805M gross proceeds\",\n          \"Royalty Pharma revenue participation: 4.5% of net sales up to $5B, 1% above $5B for aficamten products\",\n          \"Accumulated deficit $3.49B since inception; Q3 2025 first positive collaboration revenues from Bayer Japan license ($50M+ received)\"\n        ]\n      },\n      {\n        \"form\": \"10-Q\",\n        \"filed\": \"2026-05-05\",\n        \"url\": \"https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm\",\n        \"key_takeaways\": [\n          \"Q1 2026 net product revenue $4.8M from MYQORZO (first commercial quarter)\",\n          \"Total Q1 revenues: $19.4M ($4.8M product + $2.6M collaboration + $11.9M license/milestone) vs $1.58M in Q1 2025\",\n          \"Net loss Q1 2026: -$206M; operating cash burn -$145M for quarter\",\n          \"Cash/investments: $1.07B as of March 31, 2026 (decreased from $1.22B Dec 2025 due to operating burn)\",\n          \"R&D spend Q1 2026: $95.5M vs $98.3M YoY; SG&A jumped to $104.9M vs $57.4M YoY as commercial infrastructure built\",\n          \"Stockholders deficit widened to -$826.6M (from -$659.6M Dec 2025) due to operating losses\"\n        ]\n      }\n    ],\n    \"options_context\": {\n      \"expiries_examined\": [\n        \"2026-06-18\",\n        \"2026-07-17\"\n      ],\n      \"iv_summary\": \"Near-term ATM IV elevated (~54% at June 18 expiry); 16 DTE June contract shows IV ~50-55% around the money. July 17 near-term OTM calls (85 strike) show 50% IV — decent premium for CC writing.\",\n      \"notable_skew_or_flow\": \"Strong OI concentration in 80-strike call (9,881 OI at $0.75-$1.50 bid/ask spread), suggesting covered-call writers are targeting $80 as an upside ceiling. Put OI concentrated deep ITM at 35 and 60 strikes — protective puts rather than directional bearish positioning. Whale flow shows a single 1000-lot call block in the July 17 85-strike (15% OTM) with 50.4% IV suggesting an outright bull call buyer or a spread initiator.\"\n    },\n    \"competitive_landscape\": \"MYQORZO competes directly with Bristol-Myers Squibb's CAMZYOS (mavacamten), another cardiac myosin inhibitor approved for oHCM in April 2022. MAPLE-HCM showed aficamten superiority over metoprolol monotherapy — a differentiated positioning advantage vs. CAMZYOS which is typically combined with beta-blockers. The HCM market has ~400K-800K undiagnosed U.S. patients; ~300K+ diagnosed; estimated oHCM/nHCM split roughly 50/50. Competition from Edgewise Therapeutics' EDG-7500 (in development) represents a future pipeline risk.\",\n    \"key_risks\": [\n      \"Near-52w-high valuation with no earnings and high burn rate ($145M cash used in operations Q1 2026); stock would be vulnerable on any commercial disappointment\",\n      \"Competition: CAMZYOS is already established; any new entrant could pressure market share assumptions for MYQORZO\",\n      \"Clinical risk: ACACIA-HCM data (expected Q2 2026) must succeed for nHCM label expansion — failure would cap addressable market materially\",\n      \"Balance sheet stress: $826M stockholders' deficit driven by cumulative $3.7B accumulated deficit; reliant on continued capital raises or product revenue ramp to fund operations\",\n      \"REMS program requirement adds friction to prescribing and may limit initial adoption pace\",\n      \"European launch in early stages; reimbursement negotiations in EU countries could delay traction\"\n    ],\n    \"what_the_market_might_be_missing\": \"The stock's May 2026 jump (from ~$63 to $77+ on Q1 results) may have overshot near-term fair value given the heavy dilution from the $700M equity raise closed at $71/share, and the early-stage nature of commercial ramp with limited visibility. The high concentration of call OI at the $80 strike suggests institutional covered-call writing has established a clear ceiling for upside, consistent with an income/range-bound thesis rather than a momentum long.\"\n  },\n  \"anti_signals_present\": [\n    \"dilution\",\n    \"going_concern_note_in_10k\",\n    \"high_burn_rate\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"CYTK 10-K FY2025 (filed Feb 26, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm\"\n    },\n    {\n      \"label\": \"CYTK 10-Q Q1 2026 (filed May 5, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm\"\n    },\n    {\n      \"label\": \"Form 4 - CEO Blum sale Apr 29 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000044/xslF345X06/form4.xml\"\n    },\n    {\n      \"label\": \"Form 4 - EVP Malik option exercise+sale May 5 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000051/xslF345X06/form4.xml\"\n    },\n    {\n      \"label\": \"Form 4 - Dir. Kaye sale Jun 1 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000066/xslF345X06/form4.xml\"\n    },\n    {\n      \"label\": \"Form 4 - Dir. Parshall sale Jun 1 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1061983/000106198326000064/xslF345X06/form4.xml\"\n    },\n    {\n      \"label\": \"RBC: MYQORZO launch tracking ahead of expectations (May 22, 2026)\",\n      \"url\": \"https://www.marketbeat.com/instant-alerts/cytokinetics-says-mykorzo-launch-tops-expectations-as-hcm-data-draws-praise-2026-05-22/\"\n    },\n    {\n      \"label\": \"MYQORZO EU launch announcement Jun 1, 2026\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/cytokinetics-launches-myqorzo-aficamten-european-113000483.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-02T00:46:23.981Z",
      "raw_content": "<think>The dossier is for CYTK (Cytokinetics).\nScoring:\nA. Smart Money: 0 pts. Insider selling > buying. Penalty -10 pts.\nB. Options Flow: 0 pts. No whale call blocks with bullish bias and moderate/strong flow. OI at 80 strike is call writing. IV elevated ~50-54%.\nC. Catalyst: Next earnings 2026-07-29. Recent EPS surprise mixed (Q1 miss). Guidance raise in last 90d? Dossier says true. +5 pts. ACACIA-HCM data Q2 2026. +8 pts. EU launch Q2-Q4 2026. +5 pts. Total catalyst: 18 pts. (Cap 25)\nD. Mispricing: Forward P/E null. EV/EBITDA N/A. FCF yield -3.8%. SOTP null. 0 pts.\nE. Quality: ROIC null. Gross margin null. Net debt/EBITDA null. Balance sheet grade B. 0 pts.\nF. Technical: Above 50 & 200 DMA. +3 pts. 12-1 momentum +5% vs sector. +4 pts. RSI 50.7. +2 pts. MACD false. Total: 9 pts.\nTotal Score: ~32 pts.\n\nAnti-signals present: \"dilution\", \"going_concern_note_in_10k\", \"high_burn_rate\".\nThe dossier explicitly notes: \"stock is fully-valued (no forward PE given pre-profitability; EV/EBITDA N/A) and near its 52w ceiling.\"\nInsider selling is > buying.\nMarket cap: Not explicitly given, but price $73.68. Let's assume >$5B or <$5B? Actually, Cytokinetics market cap in 2026 might be around $5-7B given $700M raise at $71. Wait, $700M raise at $71 implies ~9.8M shares added. If it was ~100M shares pre, market cap ~$7.3B. So \"core\".\nBut the score is low (~32), and anti-signals are present.\nThe verdict is \"range_bound_or_income\".\nScout hints: cc, strangle.\nBut the anti-signals (dilution, going concern note, high burn rate) plus lack of mispricing and insider selling heavily point to SKIP.\nAlso, the EDGE CHECK: \"What does this idea say that the market doesn't already know?\" The market knows about the launch, the dilution, and the burn. The stock is near ATH. Writing a covered call or strangle here is just collecting premium on a fully priced stock with no clear catalyst to move it significantly higher without risk, and the anti-signals (dilution, going concern) make it a poor candidate for publication.\nI will SKIP.\nReason: Heavy insider selling, pre-profitability burn, and dilution overhang at all-time highs leave no clear asymmetric or mispriced setup; the dossier's anti-signals and lack of fundamental edge justify a skip.\nScore breakdown: A: -5 (penalty applied, min 0), B: 0, C: 18, D: 0, E: 0, F: 9. Total: 22.\nWait, rubric says penalty is -10 if material insider SELLING > BUYING. I'll set A to 0 (can't go negative per rubric usually, but I'll just put 0).\nLet's calculate strictly:\nA: 0 (penalty triggers, but base is 0)\nB: 0\nC: 18 (guidance raise 5 + catalyst 8 + EU launch 5)\nD: 0\nE: 0\nF: 9\nTotal: 27.\nSkip.\nOutput matches skip format.\nCheck constraints: \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will produce the JSON.\nDouble check score breakdown format.\n\"score_breakdown\": { \"smart_money\": 0, \"options_flow\": 0, \"catalyst\": 18, \"mispricing\": 0, \"quality\": 0, \"technical\": 9 }\n\"score\": 27\n\"reason\": \"Material insider selling, pre-profitability burn, and dilution overhang at all-time highs leave no clear asymmetric or mispriced setup; the dossier's anti-signals and lack of fundamental edge justify a skip.\"\nAll good.\nProceed. \nWait, let's verify catalyst scoring: \n10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0% -> Q1 miss, so 0.\n8 pts: pending product launch / FDA / contract milestone in horizon -> ACACIA-HCM Q2 2026. +8.\n5 pts: recent guidance raise -> +5.\n5 pts: quantifiable sector tailwind -> 0.\nTotal C = 13.\nTechnical:\n3 pts: above both 50DMA and 200DMA -> +3.\n4 pts: 12-1 month price return positive AND beating sector -> +4.\n2 pts: RSI 14 in 40-65 zone -> +2.\n1 pt: MACD bullish cross -> 0.\nTotal F = 9.\nTotal score = 0+0+13+0+0+9 = 22.\nI'll use 22.\nAll matches.\nOutput matches exactly. \nOne minor thing: The prompt says \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". I will just put 0 for smart_money as it can't go below 0 in standard scoring, or I'll put -10 if allowed, but usually scores cap at 0. I'll stick with 0.\nReady. \nOutput matches requested JSON structure.\nProceeds. \nSelf-Correction/Verification during thought:\nCheck anti-signals: \"dilution\", \"going_concern_note_in_10k\", \"high_burn_rate\". The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will note in the reason that the anti-signals apply and justify the skip.\nThe dossier clearly states it's pre-profitability with a going-concern note and high burn. Skip is correct.\nJSON structure:\n{\n  \"skip\": true,\n  \"score\": 22,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 13,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 9\n  },\n  \"reason\": \"Material insider selling, pre-profitability burn, and dilution overhang at all-time highs leave no clear asymmetric or mispriced setup; the active anti-signals (dilution, going concern, high burn) and lack of fundamental edge justify a skip.\"\n}\nMatches perfectly. Output matches. \nProceeds. \nNote: I'll make sure the JSON is valid and strictly follows the schema. No extra text.\nDone. \nOutput Generation. \n[Done] \n(Self-Correction/Refinement during generation prep)\nWait, the prompt says: \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". I will just leave it at 0 for that category since it's already 0 base.\nScore breakdown sums to 22.\nAll good.\nOutput matches. \nProceeds. \n[Output Generation] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 22,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 13,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 9\n  },\n  \"reason\": \"Material insider selling, pre-profitability burn, and dilution overhang at all-time highs leave no clear asymmetric or mispriced setup; the active anti-signals (dilution, going concern, high burn) and lack of fundamental edge justify a skip.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 22,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 13,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 9\n  },\n  \"reason\": \"Material insider selling, pre-profitability burn, and dilution overhang at all-time highs leave no clear asymmetric or mispriced setup; the active anti-signals (dilution, going concern, high burn) and lack of fundamental edge justify a skip.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 22,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 13,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 9\n  },\n  \"reason\": \"Material insider selling, pre-profitability burn, and dilution overhang at all-time highs leave no clear asymmetric or mispriced setup; the active anti-signals (dilution, going concern, high burn) and lack of fundamental edge justify a skip.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 30096,
  "stop_reason": "stop",
  "completed_at": "2026-06-02T00:46:23.981Z"
}